Ausgabe 4/2016
Inhalt (25 Artikel)
The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy
Martina Ahlmann, Georg Hempel
Mitochondria: Inadvertent targets in chemotherapy-induced skeletal muscle toxicity and wasting?
James C. Sorensen, Beatrice D. Cheregi, Cara A. Timpani, Kulmira Nurgali, Alan Hayes, Emma Rybalka
Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential significant biomarkers
Ji Hyun Park, Myung Joo Kang, Jin-Hee Ahn, Jeong Eun Kim, Kyung Hae Jung, Gyungyub Gong, Hee Jin Lee, Byung-Ho Son, Sei-Hyun Ahn, Hak-Hee Kim, Hee Jung Shin, Dae-Hyuk Moon, Sung-Bae Kim
A method for optimizing dosage regimens in oncology by visualizing the safety and efficacy response surface: analysis of inotuzumab ozogamicin
Kenneth T. Luu, Joseph Boni
Sunitinib DDI with paracetamol, diclofenac, mefenamic acid and ibuprofen shows sex-divergent effects on the tissue uptake and distribution pattern of sunitinib in mice
Siok Yean Tan, Mei Mei Wong, Angela Lu Wun Tiew, Yai Wen Choo, Suat Hun Lim, Ing Hong Ooi, Pilar Modamio, Cecilia Fernández, Eduardo L. Mariño, Ignacio Segarra
Impact of treatment duration of neoadjuvant FIRINOX in patients with borderline resectable pancreatic cancer: a pilot trial
Ken-ichi Okada, Manabu Kawai, Seiko Hirono, Sohei Satoi, Hiroaki Yanagimoto, Tatsuya Ioka, Motoki Miyazawa, Atsushi Shimizu, Yuji Kitahata, Hiroki Yamaue
Lack of pharmacokinetic drug–drug interaction between ramucirumab and irinotecan in patients with advanced solid tumors
Ding Wang, Fadi Braiteh, James J. Lee, Crystal S. Denlinger, Dale R. Shepard, Archana Chaudhary, Yong Lin, Ling Gao, Christopher Asakiewicz, Federico Nasroulah, Patricia LoRusso
Discovery of LW6 as a new potent inhibitor of breast cancer resistance protein
Jae Guen Song, Yeo Song Lee, Jin-Ah Park, Eun-Hye Lee, Soo-Jeong Lim, Seung Jun Yang, Mengjia Zhao, Kyeong Lee, Hyo-Kyung Han
Feasibility of dose-dense paclitaxel/carboplatin therapy in elderly patients with ovarian, fallopian tube, or peritoneal cancer
Seiko Bun, Mayu Yunokawa, Takahiro Ebata, Akihiko Shimomura, Tatsunori Shimoi, Makoto Kodaira, Kan Yonemori, Chikako Shimizu, Yasuhiro Fujiwara, Tomoyasu Kato, Yoshinori Makino, Yoshikazu Hayashi, Kenji Tamura
Silencing of fused toes homolog enhances cisplatin sensitivity in cervical cancer cells by inhibiting epidermal growth factor receptor-mediated repair of DNA damage
Prabakaran D. Subramanian, Zhengzhe An, Jae-Ran Yu, Woo-Yoon Park
Pharmacokinetics and pharmacogenetics of 13-cis retinoic acid in Indian high-risk neuroblastoma patients
Vikram Gota, Girish Chinnaswamy, Tushar Vora, Sanhita Rath, Akanksha Yadav, Murari Gurjar, Gareth Veal, Purna Kurkure
A phase II study of topotecan and cisplatin with sequential thoracic radiotherapy in elderly patients with small-cell lung cancer: Okayama Lung Cancer Study Group 0102
Toshio Kubo, Keiichi Fujiwara, Katsuyuki Hotta, Toshiaki Okada, Shoichi Kuyama, Shingo Harita, Takashi Ninomiya, Haruhito Kamei, Shinobu Hosokawa, Akihiro Bessho, Tadashi Maeda, Toshiyuki Kozuki, Nobukazu Fujimoto, Kiichiro Ninomiya, Mitsuhiro Takemoto, Susumu Kanazawa, Nagio Takigawa, Masahiro Tabata, Mitsune Tanimoto, Hiroshi Ueoka, Katsuyuki Kiura
Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies
Helen Swaisland, Ruth Plummer, Karen So, Sally Garnett, Wendy Bannister, Marc-Antoine Fabre, Corina Dota, Anitra Fielding
Prognostic factors from a randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and cisplatin in metastatic or recurrent cervical cancer: Japan Clinical Oncology Group (JCOG) trial: JCOG0505-S1
Shin Nishio, Ryo Kitagawa, Taro Shibata, Hiroyuki Yoshikawa, Ikuo Konishi, Kimio Ushijima, Toshiharu Kamura
Alterations of telomere length and mtDNA copy number are associated with overall survival in hepatocellular carcinoma patients treated with transarterial chemoembolization
Dengke Bao, Yanna Ba, Feng Zhou, Jing Zhao, Qi Yang, Naijian Ge, Xu Guo, Zhenbiao Wu, Hongxin Zhang, Hushan Yang, Shaogui Wan, Jinliang Xing
The metronomic therapy with prednisone, etoposide, and cyclophosphamide reduces the serum levels of VEGF and circulating endothelial cells and improves response rates and progression-free survival in patients with relapsed or refractory non-Hodgkin’s lymphoma
Jiangzheng Zeng, Liangxia Yang, Fen Huang, Tao Hong, Zhihui He, Junhua Lei, Huamao Sun, Yanda Lu, Xinbao Hao
Efficacy and safety of irinotecan monotherapy as third-line treatment for advanced gastric cancer
Takeshi Kawakami, Nozomu Machida, Hirofumi Yasui, Masahiro Kawahira, Sadayuki Kawai, Yosuke Kito, Yukio Yoshida, Satoshi Hamauchi, Takahiro Tsushima, Akiko Todaka, Tomoya Yokota, Kentaro Yamazaki, Akira Fukutomi, Yusuke Onozawa
Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer
Muhammad Wasif Saif, James A. Knost, E. Gabriela Chiorean, Siva Rama Prasad Kambhampati, Danni Yu, Bronislaw Pytowski, Amy Qin, John S. Kauh, Bert H. O’Neil
Radioimmunotherapy with 131I-rituximab as consolidation therapy for patients with diffuse large B-cell lymphoma
Dong-Yeop Shin, Byung Hyun Byun, Kyeong Min Kim, Joo Hyun Kang, Ilhan Lim, Byung Il Kim, Seung-Sook Lee, Chang Woon Choi, Hye Jin Kang, Sang Moo Lim
Impact of metronomic neoadjuvant chemotherapy on early tongue cancer
Shinichiro Kina, Toshiyuki Nakasone, Takao Kinjo, Tessho Maruyama, Toshihiro Kawano, Akira Arasaki
A pilot study of concurrent chemoradiotherapy with gemcitabine and cisplatin in patients with locally advanced biliary tract cancer
Kyong Joo Lee, Seung Woo Yi, Jihye Cha, Jinsil Seong, Seungmin Bang, Si Young Song, Hee Man Kim, Seung Woo Park
Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure–response analysis
Kevin J. Freise, Martin Dunbar, Aksana K. Jones, David Hoffman, Sari L. Heitner Enschede, Shekman Wong, Ahmed Hamed Salem
Association of axitinib plasma exposure and genetic polymorphisms of ABC transporters with axitinib-induced toxicities in patients with renal cell carcinoma
Hiroshi Kato, Naoto Sassa, Masayuki Miyazaki, Mio Takeuchi, Miho Asai, Akane Iwai, Yukihiro Noda, Momokazu Gotoh, Kiyofumi Yamada
Intestinal permeability to iohexol as an in vivo marker of chemotherapy-induced gastrointestinal toxicity in Sprague–Dawley rats
Richard A. Forsgård, Riitta Korpela, Reetta Holma, Jere Lindén, Rafael Frias, Thomas Spillmann, Pia Österlund
Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines
Didier Meulendijks, Linda M. Henricks, André B. P. van Kuilenburg, Bart A. W. Jacobs, Abidin Aliev, Lisette Rozeman, Judith Meijer, Jos H. Beijnen, Hiltje de Graaf, Annemieke Cats, Jan H. M. Schellens